Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Mar 2026

Chirra Martina, Elliott Andrew, Shaikh Hira, McGrath Julie, El-Gamal Dalia, Karnezis Anthony Nicholas, Abdulla Farah R, Ikpeazu Chukwuemeka, Leddon Jennifer, Sukari Ammar, Zandberg Dan P, Johnson Jennifer Maria, Sun Lova, Wise-Draper Trisha M

Abstract excerpt

PURPOSE: Radioactive iodine-refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E-mutated (BRAF-mut) and BRAF wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41543354
DOI: 10.1158/1078-0432.CCR-25-3932

Genes

BRAF
ETV6
HRAS
KRAS
NRAS
RET
TERT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.PMID 41543354Read ↗

A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.Semantic proximity Read ↗

Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.Semantic proximity Read ↗

Leveraging the transcriptome-phenotype relationship to guide clinical management of papillary thyroid cancer.Semantic proximity Read ↗

Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.Semantic proximity Read ↗

BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.Semantic proximity Read ↗

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.Semantic proximity Read ↗

Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical OutcomesSemantic proximity Read ↗

Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation statusSemantic proximity Read ↗

Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.Semantic proximity Read ↗

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.Semantic proximity Read ↗

Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.